The present study has some limitations: a lack of data regarding TLR2, TLR4, and TLR9 gene expression, and CEBPA, IDH1, IDH2, etc., mutation status was not investigated in all cases and heterogeneity of the AML patients included in the study (different AML subtype). The gene discussed is IDH2; the disease is acute myeloid leukemia.